Kling Andreas, Jantos Katja, Mack Helmut, Hornberger Wilfried, Drescher Karla, Nimmrich Volker, Relo Ana, Wicke Karsten, Hutchins Charles W, Lao Yanbin, Marsh Kennan, Moeller Achim
Neuroscience Research, AbbVie Deutschland GmbH & Co. KG , Knollstrasse, 67061 Ludwigshafen, Germany.
AbbVie Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064-6125, United States.
J Med Chem. 2017 Aug 24;60(16):7123-7138. doi: 10.1021/acs.jmedchem.7b00731. Epub 2017 Aug 15.
Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and reversible inhibitors of calpain with high selectivity versus related cysteine protease cathepsins, other proteases, and receptors. Broad efficacy in a set of preclinical models relevant to AD suggests that inhibition of calpain represents an attractive approach with potential benefit for the treatment of AD.
钙蛋白酶过度激活与多种病理疾病有关,包括缺血/再灌注损伤、白内障形成以及神经退行性疾病如阿尔茨海默病(AD)。在此,我们描述了我们的研究工作,这些工作导致了基于酮酰胺的2-(3-苯基-1H-吡唑-1-基)烟酰胺的鉴定,该化合物是钙蛋白酶的有效且可逆的抑制剂,对相关半胱氨酸蛋白酶组织蛋白酶、其他蛋白酶和受体具有高选择性。在一组与AD相关的临床前模型中的广泛疗效表明,抑制钙蛋白酶是一种有吸引力的方法,对AD的治疗可能有益。